1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors.
Saved in:
| Title: | 1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. |
|---|---|
| Authors: | Tran, B.1 (AUTHOR), Millward, M.2 (AUTHOR), Lemech, C.3 (AUTHOR), Frentzas, S.4 (AUTHOR), Day, D.4 (AUTHOR), Latifi, A.5 (AUTHOR), Desai, J.1 (AUTHOR), Wabnitz, P.5 (AUTHOR), Kearney, P.5 (AUTHOR), Galkin, A.5 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS635-S635. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
